News

Enlarge image

FundingEUGermanyFranceDenmark

Vaccine vs placental malaria

04.03.2013 - Researchers from the PlacMalVac project have bagged €6m from the EU to start clinical trials of a placental malaria vaccine.

Pregnant women are particularly vulnerable to malaria, due to a particular type of pathology. Their infected blood cells clump together in the placenta, leading to growth retardation and preterm delivery, which in turn cause higher infant mortality. For the first time, a EU consortium of 5 partners led by University of Copenhagen will now begin clinical trials with a vaccine that blocks that blood aggregation in placenta-associated malaria (PAM). It targets the var2CSA protein, which causes aggregation of Plasmodium falciparum-infected erythrocytes by adhesion to the primary placental adherence receptor, chondroitin sulphate A (CSA), present in the placental intervillous blood spaces. Infected mice not carrying var2CSA do not show the PAM-associated effects.

“This will be the first clinical trial using the parasite antigens", said project coordinator Thor G. Theander from the University of Copenhagen. "The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity. It marks an intermediate highpoint of many years of committed research.”

In previous projects supported by the Danish National Advanced Technology Foundation, Theander's team defined a smaller region of multi-domain protein var2CSA. Overall they identified three antigenic regions within it that are crucial for blocking PAM in rats. "We managed proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Theander now heads the EU consortium, which includes University of Copenhagen, ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), Université d'Abomey-Calavi (Benin), University of Tübingen and the European Vaccine Initiative (EVI). The EVI has mobilised further €10m for the development of PAM vaccines within the projects PRIMALVAC and PAMCPH.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/vaccine-vs-placental-malaria.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.25 EUR5.00%
  • SAREUM HOLDINGS (UK)0.24 GBP4.35%
  • SCANCELL HOLDINGS (UK)18.25 GBP4.29%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • IMMUPHARMA (UK)25.50 GBP-12.07%

TOP

  • EPIGENOMICS (D)4.46 EUR98.2%
  • THERAMETRICS (CH)0.05 CHF25.0%
  • WILEX (D)2.09 EUR19.4%

FLOP

  • PROTHENA PLC (IE)34.27 USD-37.2%
  • PLETHORA (UK)2.75 GBP-35.1%
  • BIONOR PHARMA (N)0.88 NOK-34.8%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 05.02.2016